Product Code: IRTNTR7469
About HIV
HIV is a type of retrovirus that causes infection in human beings. AIDS is a life-threatening disease caused by this virus. In this disease certain white blood cells (lymphocytes) are destroyed, resulting in the loss of the body's ability to protect itself against infections. The major route of transmission of HIV infection is unprotected sex, contaminated needle, breast milk, and infected blood. HIV attacks the body's white blood cells, specifically a subset called CD4 or helper T cells. The anti-retroviral therapy is used to treat the patient and help the immune system fight the infection. This is mainly used to keep the level of the HIV low in the body.
Technavio's analysts forecast the global HIV drugs market to grow at a CAGR of 4.52% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global HIV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic and branded drugs and the expected launch of drug candidates used in the treatment of HIV infection.
Based on the class of drugs, the market is segmented as follows:
- Multi-class combination products
- Nucleoside reverse transcriptase inhibitors
- Non-nucleoside reverse transcriptase inhibitors
- Protease inhibitors
- Fusion inhibitors
- Entry inhibitors - CCR5 co-receptor antagonist
- HIV integrase strand transfer inhibitors
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.
Technavio's report, Global HIV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
Key vendors
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
Other Prominent Vendors
- AbbVie
- AstraZeneca
- Boehringer Ingelheim
- Cipla
- Daiichi Sankyo
- Emcure
- F. Hoffmann-La Roche
- Hetero Drugs
- Mylan
- Pfizer
- Shionogi
- Teva Pharmaceutical Industries
Market driver
- Inflow of funds
- For a full, detailed list, view our report
Market challenge
- Patent expiries
- For a full, detailed list, view our report
Market trend
- Increasing public awareness
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
PART 05: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 06: Market segmentation by drug class
PART 07: Global multi-class combination products market
- Global multi-class combination products market
PART 08: Global nucleoside reverse transcriptase inhibitors market
- Global nucleoside reverse transcriptase inhibitors market
PART 09: Global non-nucleoside reverse transcriptase inhibitors market
- Global non-nucleoside reverse transcriptase inhibitors market
PART 10: Global protease inhibitors market
- Global protease inhibitors market
PART 11: Global fusion inhibitors market
- Global fusion inhibitors market
PART 12: Global entry inhibitors - CCR5 co-receptor antagonist market
- Global entry inhibitors - CCR5 co-receptor antagonist market
PART 13: Global HIV integrase strand transfer inhibitors market
- Global HIV integrase strand transfer inhibitors market
PART 14: Geographical segmentation
- Global HIV drugs market segmentation by geography
PART 15: Market drivers
- Increased funding
- Rise in patient population
- Unmet medical needs
- Initiatives by governments
PART 16: Impact of drivers
PART 17: Market challenges
- Expiry of patents
- Associated social stigma
- Side effects of drugs
- Complications in disease diagnosis
PART 18: Impact of drivers and challenges
PART 19: Market trends
- Rise in public awareness
- Strategic alliances
- Novel approaches
PART 20: US Government: Funding for HIV
PART 21: Vendor landscape
- Competitive scenario
- Market share analysis
- Other prominent vendors
PART 22: Key vendor analysis
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
PART 23: Appendix
PART 24: Explore Technavio
List of Exhibits
- Exhibit 01: Product offerings
- Exhibit 02: Global HIV drugs market 2014-2019 ($ millions)
- Exhibit 03: Five forces analysis
- Exhibit 04: Global HIV drugs market segmentation by drug class 2014
- Exhibit 05: Global HIV drugs market segmentation by drug class 2014-2019 ($ millions)
- Exhibit 06: Global multi-class combination products market 2014-2019 ($ millions)
- Exhibit 07: Global nucleoside reverse transcriptase inhibitors market 2014-2019 ($ millions)
- Exhibit 08: Global non-nucleoside reverse transcriptase inhibitors market 2014-2019 ($ millions)
- Exhibit 09: Global protease inhibitors market 2014-2019 ($ millions)
- Exhibit 10: Global fusion inhibitors market 2014-2019 ($ millions)
- Exhibit 11: Global entry inhibitors - CCR5 co-receptor antagonist market 2014-2019 ($ millions)
- Exhibit 12: Global HIV integrase strand transfer inhibitors market 2014-2019 ($ millions)
- Exhibit 13: Global HIV drugs market segmentation by geography 2014
- Exhibit 14: Global HIV drugs market segmentation by geography 2014-2019 ($ millions)
- Exhibit 15: HIV drugs market in Americas 2014-2019 ($ millions)
- Exhibit 16: HIV drugs market in EMEA 2014-2019 ($ millions)
- Exhibit 17: HIV drugs market in APAC 2014-2019 ($ millions)
- Exhibit 18: Assistance from donor governments for HIV treatment 2013
- Exhibit 19: Global HIV statistics 2014
- Exhibit 20: Impact of drivers
- Exhibit 21: Impact of drivers and challenges
- Exhibit 22: Funding by the US government for HIV 2010-2016 ($ billions)
- Exhibit 23: Funding by the US government for domestic treatment and care of HIV 2010-2016 ($ billions)
- Exhibit 24: Bristol-Myers Squibb: Revenue of Reyataz 2012-2014 ($ billions)
- Exhibit 25: Bristol-Myers Squibb: Revenue of Sustiva 2012-2014 ($ billions)
- Exhibit 26: Gilead Sciences: Revenue of Stribild 2012-2014 ($ millions)
- Exhibit 27: Gilead Sciences: Revenue of Truvada 2012-2014 ($ billions)
- Exhibit 28: Gilead Sciences: Revenue of Emtriva 2012 and 2013 ($ millions)
- Exhibit 29: Gilead Sciences: Revenue of Atripla 2012-2014 ($ billions)
- Exhibit 30: Gilead Sciences: Revenue of Complera/Eviplera 2012-2014 ($ millions)
- Exhibit 31: Gilead Sciences: Revenue of Viread 2012-2014 ($ millions)
- Exhibit 32: GlaxoSmithKline: Revenue of Combivir 2012-2014 ($ millions)
- Exhibit 33: GlaxoSmithKline: Revenue of Trizivir 2012-2014 ($ millions)
- Exhibit 34: GlaxoSmithKline: Revenue of Agenerase and Lexiva 2012-2014 ($ millions)
- Exhibit 35: GlaxoSmithKline: Revenue of Tivicay 2013-2014 ($ millions)
- Exhibit 36: Johnson & Johnson: Revenue of Edurant 2012-2014 ($ millions)
- Exhibit 37: Johnson & Johnson: Revenue of Prezista 2012-2014 ($ billions)
- Exhibit 38: Merck: Revenue of Isentress 2012-2014 ($ billions)
